CD80 and neoplasm: The changes to iMoDC surface phenotype are likely to be tumor-driven, as exposure to Met5A cells did not alter the percent of CD1a+, CD86+ or CD80+ iMoDCs (S2B—S2D Fig), nor did it alter surface expression levels (MFIs) of CD86 or CD80 on iMoDCs, relative to DCs only (S2E and S2F Fig).